GGrantIndex
← Leaderboards

Zhengrong Cui

Oregon State University

$6,259,250
Attributed
$6,921,534
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $925.1K · FY200725
$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,921,534 · 9

By mechanism

R01$5,287,329 · 4
R21$1,175,031 · 3
R41$314,363 · 1
R03$144,811 · 1

Top collaborators

Others in their field

Top investigators on “Base

Research focus

BaseFutureFoundationsNovel StrategiesMouse ModelImmune ResponseInnovationInjection Of Therapeutic AgentModalityTumor GrowthClinical TrialsNeoplastic CellAffectTumorMalignant NeoplasmsGemcitabineSurfaceCellsCancer TherapyPreventChemotherapyCancer ModelLungValidation

Grant awards (30)

Microneedle-based mRNA Flu Vaccine for Transcutaneous Immunization$314,363
R41 · FY2025 · AI
Biomedical Applications of Expanded Porphyrins: Development of Gold-Texaphyrin Conjugates$349,603
R01 · FY2019 · CA
Biomedical Applications of Expanded Porphyrins: Development of Gold-Texaphyrin Conjugates$360,416
R01 · FY2018 · CA
Receptor and Carriers for Coupled Ion Transport$300,186
R01 · FY2018 · GM
Overcoming pancreatic tumor resistance to gemcitabine$310,970
R01 · FY2017 · CA · contact PI
Overcoming pancreatic tumor resistance to gemcitabine$310,970
R01 · FY2016 · CA · contact PI
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy$202,928
R21 · FY2016 · CA · contact PI
Overcoming pancreatic tumor resistance to gemcitabine$310,970
R01 · FY2015 · CA · contact PI
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy$168,563
R21 · FY2015 · CA · contact PI
Overcoming pancreatic tumor resistance to gemcitabine$301,641
R01 · FY2014 · CA · contact PI
An innovative approach to improve the activity of an aluminum-containing adjuvant$231,140
R21 · FY2014 · AI · contact PI
Overcoming pancreatic tumor resistance to gemcitabine$310,886
R01 · FY2013 · CA · contact PI
An innovative approach to improve the activity of an aluminum-containing adjuvant$193,274
R21 · FY2013 · AI · contact PI
Topical DNA immunization by modifying the hair follicle cycle$359,734
R01 · FY2011 · AI · contact PI
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine$293,365
R01 · FY2011 · CA · contact PI
Topical DNA immunization by modifying the hair follicle cycle$364,535
R01 · FY2010 · AI · contact PI
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine$303,617
R01 · FY2010 · CA · contact PI
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine$275,583
R01 · FY2009 · CA · contact PI
Topical DNA immunization by modifying the hair follicle cycle$231,737
R01 · FY2009 · AI · contact PI
Topical DNA immunization by modifying the hair follicle cycle$120,105
R01 · FY2009 · AI · contact PI
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine$99,534
R01 · FY2009 · CA · contact PI
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine$21,803
R01 · FY2009 · CA · contact PI
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine$13,867
R01 · FY2009 · CA · contact PI
Topical DNA immunization by modifying the hair follicle cycle$354,412
R01 · FY2008 · AI · contact PI
Combination therapy using tumor-targeting synthetic dsRNA and gemcitabine$293,395
R01 · FY2008 · CA · contact PI
A tri-antigen nasal anthrax vaccine against toxins and vegetative bacilli$113,015
R21 · FY2008 · AI · contact PI
A tri-antigen nasal anthrax vaccine against toxins and vegetative bacilli$92,601
R21 · FY2008 · AI · contact PI
Anthrax DNA vaccine for non-invasive immunization on skin$71,711
R03 · FY2008 · AI · contact PI
A tri-antigen nasal anthrax vaccine against toxins and vegetative bacilli$173,510
R21 · FY2007 · AI · contact PI
Anthrax DNA vaccine for non-invasive immunization on skin$73,100
R03 · FY2007 · AI · contact PI